Edition:
United Kingdom

Ipsen And 3BP Announce First Patient Dosed In IPN01087 Phase I/II Study


Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - IPSEN SA ::IPSEN AND 3BP ANNOUNCE FIRST PATIENT DOSED IN PHASE I/II STUDY FOR FIRST-IN-CLASS RADIONUCLIDE (IPN01087).KEY OBJECTIVE OF PHASE I DOSE-ESCALATION TRIAL (EUDRACT NUMBER 2017-001263-20) IS TO EVALUATE SAFETY AND ACTIVITY.IPN01087 IS A COMPOUND THAT TARGETS CANCER CELLS IN PATIENTS WITH ADVANCED SOLID TUMORS WHICH EXPRESS NEUROTENSIN RECEPTOR SUBTYPE 1 (NTSR1). 

Company Quote

118.5
 --
18 Jun 2019